1. GRAIL Faces Analyst Downgrades After Key Study Setback, Mizuho & Piper Sandler Cut Ratings
GRAIL, the cancer detection company, has been hit with analyst downgrades from two major firms following a significant setback in a clinical study. Mizuho and Piper Sandler both lowered their ratings on the stock, signaling a sharp loss of confidence from Wall Street in the near-term prospects for GRAIL's flagship mult...